Skip to main content

Endogenous opioid peptides: historical aspects

  • Chapter
Centrally Acting Peptides

Part of the book series: Biological Council

Abstract

This short chapter serves as an introduction to the following contributions on endogenous opioid peptides and gives some of the more important historical developments in the search for an endogenous ligand for the opiate receptors. One general point has attracted our interest for some time, namely the fact that certain alkaloids found in plants have functional correlates in animal tissues. Although there are certain structural similarities between the two classes of compounds, the plant alkaloids are much more resistant to enzymic inactivation in animal tissues than the corresponding compounds of animal origin, and for this reason are often potent neurotoxic agents. Examples of such pairs of compounds are muscarine and muscimol, derived from the toadstool Amanita muscaria, which correspond to the neurotransmitters acetylcholine and γ-aminobutyric acid (GABA), respectively. Other pairs are nicotine and acetylcholine and also ephedrine and noradrenaline. To these may now be added morphine from Papaver somniferum and the class of peptides known as enkephalins and endorphins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akil, H., Mayer, D. J. and Liebeskind, J. C. (1972). Cr. hebd. Séanc. Acari Sci. Paris, 274, 3603–05

    Google Scholar 

  • Hughes, J. (1975). Brain Res., 88, 295–308

    Article  Google Scholar 

  • Hughes, J., Kosterlitz, H. W. and Leslie, F. M. (1975a). Br. J. Pharmac, 53, 371–81

    Article  Google Scholar 

  • Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A. and Morris, H. R. (1975b). Nature, 258, 577–79

    Article  Google Scholar 

  • Kosterlitz, H. W. and Waterfield, A. A. (1975). A. Rev. Pharmac., 15, 29–47

    Article  Google Scholar 

  • Kosterlitz, H. W. and Watt, A. J. (1968). Br. J. Pharmac., 33, 266–76

    Google Scholar 

  • Paton, W. D. M. (1957). Br. J. Pharmac., 12, 119–27

    Google Scholar 

  • Pert, C. B. and Snyder, S. H. (1973). Science, 179, 1011–14

    Article  Google Scholar 

  • Simon, E. J., Hiller, J. M. and Edelman, I. (1973). Proc. natn. Acad. Sci. U.S.A., 70, 1947–49

    Article  Google Scholar 

  • Terenius, L. (1973). Acta pharmac. tox., 33, 377–84

    Article  Google Scholar 

  • Trendelenburg, P. (1917). Naunyn-Schmiedebergs Arch. exp. Path. Pharmak., 81, 55–129

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Copyright information

© 1978 Institute of Biology Endowment Trust Fund

About this chapter

Cite this chapter

Kosterlitz, H.W. (1978). Endogenous opioid peptides: historical aspects. In: Hughes, J. (eds) Centrally Acting Peptides. Biological Council. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-03668-4_10

Download citation

Publish with us

Policies and ethics